NCT00157209, a Phase IIb randomized controlled trial, evaluated the safety and efficacy of Tecemotide, a MUC1-targeting vaccine, in combination with best supportive care (BSC) for patients with stage IIIb or IV NSCLC who had stable disease or response after first-line therapy (chemotherapy ± radiotherapy). Here, MUC1 is linked to non-small cell lung carcinoma.